{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:22Z","timestamp":1740107002190,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T00:00:00Z","timestamp":1455235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"DOI":"10.1007\/s00520-016-3078-5","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T05:57:20Z","timestamp":1455256640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Trends in anemia treatment among patients with five non-myeloid malignancies treated with chemotherapy in a large integrated health care delivery system in California, 2000\u20132013"],"prefix":"10.1007","author":[{"given":"Lanfang","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hairong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Cannavale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Sattayapiwat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Page","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6072-4954","authenticated-orcid":false,"given":"Chun","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,12]]},"reference":[{"key":"3078_CR1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1548-5315(11)70353-9","volume":"6","author":"S Shord","year":"2009","unstructured":"Shord S, Auerbach M (2009) Treating chemotherapy-induced anemia following the revised labeling for ESAs. Commun Oncol 6:279\u2013282","journal-title":"Commun Oncol"},{"issue":"Suppl 2","key":"3078_CR2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000088282","volume":"69","author":"P Harper","year":"2005","unstructured":"Harper P, Littlewood T (2005) Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology 69(Suppl 2):2\u20137","journal-title":"Oncology"},{"issue":"33","key":"3078_CR3","doi-asserted-by":"crossref","first-page":"8296","DOI":"10.1200\/JCO.2005.10.167","volume":"23","author":"P Nieboer","year":"2005","unstructured":"Nieboer P, Buijs C, Rodenhuis S et al (2005) Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol : Off J Am Soc Clin Oncol 23(33):8296\u20138304","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"6","key":"3078_CR4","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/107327480301000606","volume":"10","author":"L Balducci","year":"2003","unstructured":"Balducci L (2003) Anemia, cancer, and aging. Cancer Control 10(6):478\u2013486","journal-title":"Cancer Control"},{"issue":"12","key":"3078_CR5","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","volume":"91","author":"JJ Caro","year":"2001","unstructured":"Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91(12):2214\u20132221","journal-title":"Cancer"},{"issue":"11A","key":"3078_CR6","first-page":"369","volume":"12","author":"D Cella","year":"1998","unstructured":"Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W (1998) Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 12(11A):369\u2013377","journal-title":"Oncology (Williston Park)"},{"issue":"6","key":"3078_CR7","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdh235","volume":"15","author":"D Cella","year":"2004","unstructured":"Cella D, Kallich J, McDermott A, Xu X (2004) The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol : Off J Eur Soc Med Oncol \/ ESMO 15(6):979\u2013986","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol \/ ESMO"},{"issue":"5","key":"3078_CR8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.5-5-353","volume":"5","author":"GA Curt","year":"2000","unstructured":"Curt GA, Breitbart W, Cella D et al (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5(5):353\u2013360","journal-title":"Oncologist"},{"issue":"2","key":"3078_CR9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00019053-200523020-00009","volume":"23","author":"E Berndt","year":"2005","unstructured":"Berndt E, Crown W, Kallich J, Long S, Song X, Lyman GH (2005) The impact of anaemia and its treatment on employee disability and medical costs. Pharmacoeconomics 23(2):183\u2013192","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"3078_CR10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2165\/00019053-200523050-00009","volume":"23","author":"E Berndt","year":"2005","unstructured":"Berndt E, Kallich J, McDermott A, Xu X, Lee H, Glaspy J (2005) Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics 23(5):505\u2013514","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"3078_CR11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00520-007-0380-2","volume":"16","author":"DH Henry","year":"2008","unstructured":"Henry DH, Viswanathan HN, Elkin EP, Traina S, Wade S, Cella D (2008) Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. Support Care Cancer: Off J Multinatl Assoc Support Care Cancer 16(7):791\u2013801","journal-title":"Support Care Cancer: Off J Multinatl Assoc Support Care Cancer"},{"issue":"2","key":"3078_CR12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1524-4733.2005.03089.x","volume":"8","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Berndt ER, Kallich JD et al (2005) The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 8(2):149\u2013156","journal-title":"Value Health"},{"issue":"1","key":"3078_CR13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bpa.2012.11.006","volume":"27","author":"LT Goodnough","year":"2013","unstructured":"Goodnough LT, Shander A (2013) Update on erythropoiesis-stimulating agents. Best Pract Res Clin Anaesthesiol 27(1):121\u2013129","journal-title":"Best Pract Res Clin Anaesthesiol"},{"issue":"3","key":"3078_CR14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/sj.bjc.6600465","volume":"87","author":"JA Glaspy","year":"2002","unstructured":"Glaspy JA, Jadeja JS, Justice G et al (2002) Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 87(3):268\u2013276","journal-title":"Br J Cancer"},{"key":"3078_CR15","volume":"3","author":"J Bohlius","year":"2006","unstructured":"Bohlius J, Wilson J, Seidenfeld J et al (2006) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 3, CD003407","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"3078_CR16","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.clinthera.2006.06.003","volume":"28","author":"SD Ross","year":"2006","unstructured":"Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT (2006) Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 28(6):801\u2013831","journal-title":"Clin Ther"},{"issue":"25","key":"3078_CR17","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1200\/JCO.2005.06.150","volume":"23","author":"B Leyland-Jones","year":"2005","unstructured":"Leyland-Jones B, Semiglazov V, Pawlicki M et al (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol : Off J Am Soc Clin Oncol 23(25):5960\u20135972","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"9392","key":"3078_CR18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","volume":"362","author":"M Henke","year":"2003","unstructured":"Henke M, Laszig R, Rube C et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362(9392):1255\u20131260","journal-title":"Lancet"},{"issue":"7","key":"3078_CR19","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2007.14.2885","volume":"26","author":"RE Smith Jr","year":"2008","unstructured":"Smith RE Jr, Aapro MS, Ludwig H et al (2008) Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol : Off J Am Soc Clin Oncol 26(7):1040\u20131050","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"9","key":"3078_CR20","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2006.07.1514","volume":"25","author":"JR Wright","year":"2007","unstructured":"Wright JR, Ung YC, Julian JA et al (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol : Off J Am Soc Clin Oncol 25(9):1027\u20131032","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"11","key":"3078_CR21","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-07-1872","volume":"14","author":"V Juneja","year":"2008","unstructured":"Juneja V, Keegan P, Gootenberg JE et al (2008) Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clin Cancer Res 14(11):3242\u20133247","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3078_CR22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1200\/JOP.0863501","volume":"4","author":"K Hagerty","year":"2008","unstructured":"Hagerty K (2008) Continued regulatory actions affecting the use of erythropoiesis-stimulating agents. J Oncol Pract 4(6):267\u2013270","journal-title":"J Oncol Pract"},{"key":"3078_CR23","unstructured":"U.S. Food and Drug Administration. Risk evaluation and mitigation strategy (REMS). 2013; http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM200105.pdf , 2015"},{"key":"3078_CR24","unstructured":"U.S. Food and Drug Administration. Information on erythropoiesis-stimulating agents (ESA) epoetin alfa (marketed as Procrit, Epogen), darbepoetin alfa (marketed as Aranesp). 2015; http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm109375.htm , 2015"},{"key":"3078_CR25","unstructured":"U.S. Food and Drug Administration. Postmarket Drug Safety Information for Patients and Providers. 2011; http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM152180.pdf , 2015"},{"issue":"12","key":"3078_CR26","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1634\/theoncologist.2010-0293","volume":"15","author":"S Vadhan-Raj","year":"2010","unstructured":"Vadhan-Raj S, Zhou X, Sizer K et al (2010) Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusions. Oncologist 15(12):1359\u20131369","journal-title":"Oncologist"},{"issue":"6","key":"3078_CR27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1548-5315(11)70349-7","volume":"6","author":"B Feinberg","year":"2009","unstructured":"Feinberg B, Gilmore J, Gondesen T et al (2009) Impact of NCD guidelines on Medicare patients with chemotherapy-induced anemia receiving erythropoiesis-stimulating agents: results from a community oncology practice. Community Oncol 6(6):257\u2013261","journal-title":"Community Oncol"},{"issue":"4","key":"3078_CR28","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1078155210382318","volume":"17","author":"JM Yu","year":"2011","unstructured":"Yu JM, Shord SS, Cuellar S (2011) Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia. J Oncol Pharm Pract : Off Publ Int Soc Oncol Pharm Pract 17(4):360\u2013365","journal-title":"J Oncol Pharm Pract : Off Publ Int Soc Oncol Pharm Pract"},{"issue":"4","key":"3078_CR29","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1177\/147323001204000433","volume":"40","author":"JW Hill","year":"2012","unstructured":"Hill JW, Cong Z, Hess G, McGarvey N, Nordyke RJ (2012) Hemoglobin decline in chemotherapy patients prior to and after policy changes affecting use of erythropoiesis-stimulating agents: 2006\u20132009. J Int Med Res 40(4):1532\u20131545","journal-title":"J Int Med Res"},{"issue":"1","key":"3078_CR30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JOP.2011.000268","volume":"8","author":"BA Feinberg","year":"2012","unstructured":"Feinberg BA, Bruno AS, Haislip S, Gilmore J, Jain G, Whyte JL (2012) Hemoglobin trends and anemia treatment resulting from concomitant chemotherapy in community oncology clinics. J Oncol Pract 8(1):18\u201323","journal-title":"J Oncol Pract"},{"key":"3078_CR31","doi-asserted-by":"crossref","unstructured":"Burton T, Larholt K, Apgar E (2008) Pre- vs. post-national coverage determination (NCD) blood utilization and hemoglobin values among Medicare patients treated with erythropoietic-stimulating agents (ESAS) for chemotherapy-induced anemia (CIA). Presented at 50th Annual Meeting of the American Society of Hematology presented at; San Francisco, CA, USA","DOI":"10.1182\/blood.V112.11.1301.1301"},{"key":"3078_CR32","doi-asserted-by":"crossref","unstructured":"Apgar E, Burton T, Larholt K (2009) Hematologic and hospitalization outcomes in patients with chemotherapy-induced anemia (CIA) treated with erythropoiesis-stimulating agents (ESAs) in the pre- vs post-national coverage (NCD) time periods. Presented at 51st Annual Meeting of the American Society of Hematology presented at; New Orleans, LA, USA","DOI":"10.1182\/blood.V114.22.2482.2482"},{"key":"3078_CR33","unstructured":"DiBona J, Lichtig L, Green L (2009) Retrospective cohort study of transfusion rates in cancer patients before and after implementation of the Medicare national coverage (NCD) restricting coverage for erythropoiesis-stimulating agents (ESAs). . Presented at American Society of Health-System Pharmacists 2009 Summer Meeting presented at; Rosemont, IL, USA"},{"issue":"8","key":"3078_CR34","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/pds.3257","volume":"21","author":"TJ Arneson","year":"2012","unstructured":"Arneson TJ, Li S, Gilbertson DT, Bridges KR, Acquavella JF, Collins AJ (2012) Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients. Pharmacoepidemiol Drug Saf 21(8):857\u2013864","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"3078_CR35","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s00520-011-1318-2","volume":"20","author":"DH Henry","year":"2012","unstructured":"Henry DH, Langer CJ, McKenzie RS et al (2012) Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer 20(9):2089\u20132096","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"issue":"11","key":"3078_CR36","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ajh.21837","volume":"85","author":"G Hess","year":"2010","unstructured":"Hess G, Nordyke RJ, Hill J, Hulnick S (2010) Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions. Am J Hematol 85(11):838\u2013843","journal-title":"Am J Hematol"},{"issue":"2","key":"3078_CR37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/IGC.0b013e318276d9da","volume":"23","author":"JD Boone","year":"2013","unstructured":"Boone JD, Fauci JM, Walters CL, Whitworth JM, Bevis KS, Alvarez RD (2013) The effect of the APPRISE mandate on use of erythropoiesis-stimulating agents and transfusion rates in patients with ovarian cancer receiving chemotherapy. Int J Gynecol Cancer : Off J Int Gynecol Cancer Soc 23(2):367\u2013371","journal-title":"Int J Gynecol Cancer : Off J Int Gynecol Cancer Soc"},{"key":"3078_CR38","doi-asserted-by":"crossref","unstructured":"Burton T, Boulanger L, Larholt K (2009) Blood and resource utilization in cancer patients with chemotherapy-induced anemia (CIA) in the pre- and post- national coverage determination (NCD) timeframes: results from an electronic medical record story. Presented at 51st Annual Meeting of the American Society of Hematology presented at; New Orleans, LA, USA","DOI":"10.1182\/blood.V114.22.2472.2472"},{"issue":"8","key":"3078_CR39","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s00520-011-1255-0","volume":"20","author":"E Tarlov","year":"2012","unstructured":"Tarlov E, Stroupe KT, Lee TA et al (2012) Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002\u20132008. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer 20(8):1649\u20131657","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"key":"3078_CR40","doi-asserted-by":"crossref","unstructured":"Batty N, Ghonimi E, Feng L (2010) Blood transfusion and erythropoiesis agents (ESAs) use in patients with diffuse large B-cell lymphoma (DLBCL). Presented at 52nd Annual Meeting of the American Society of Hematology presented at; Orlando, Fl, USA","DOI":"10.1182\/blood.V116.21.3357.3357"},{"key":"3078_CR41","doi-asserted-by":"crossref","unstructured":"Dickinson K, Sakr B (2012) ESA use in women with cancer: Consequences of the 2008 FDA clinical alert. Presented at American Society of Clinical Oncology 2012 Annual Meeting presented at; Chicago, IL, USA","DOI":"10.1200\/jco.2012.30.15_suppl.5040"},{"key":"3078_CR42","doi-asserted-by":"crossref","unstructured":"Naeim A, Glaspy J (2008) Changes in RBC supportive medications and transfusions in cancer patients undergoing chemotherapy before and after FDA and Medicare actions in 2007. Presented at American Society of Clinical Oncology 2008 Annual Meeting presented at","DOI":"10.1200\/jco.2008.26.15_suppl.20595"},{"issue":"3","key":"3078_CR43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7812\/TPP\/12-031","volume":"16","author":"C Koebnick","year":"2012","unstructured":"Koebnick C, Langer-Gould AM, Gould MK et al (2012) Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J 16(3):37\u201341","journal-title":"Perm J"},{"key":"3078_CR44","unstructured":"Pharmacists ASoH-S. AFHS Drug Information. AFHS 2013 Drug Information ed. Bethesda, MD2013"},{"key":"3078_CR45","unstructured":"Lexi-Comp. Lexi-Comp I. Drug Information Handbook, 21st ed. ed. Hudson, OH2013"},{"issue":"5","key":"3078_CR46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/17474086.2014.943730","volume":"7","author":"H Xu","year":"2014","unstructured":"Xu H, Kaye JA, Saltus CW, Crawford J, Gasal E, Goodnough LT (2014) Blood utilization and hemoglobin levels in cancer patients after label and coverage changes for erythropoiesis-stimulating agents. Expert Rev Hematol 7(5):617\u2013633","journal-title":"Expert Rev Hematol"},{"issue":"33","key":"3078_CR47","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1200\/JCO.2010.29.2201","volume":"28","author":"JD Rizzo","year":"2010","unstructured":"Rizzo JD, Brouwers M, Hurley P et al (2010) American Society of Clinical Oncology\/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol : Off J Am Soc Clin Oncol 28(33):4996\u20135010","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"3078_CR48","unstructured":"Rodgers G, Gilreath J, Cella D, al. e. NCCN clinical practice guidelines in oncology: cancer-and chemotherapy-induced anemia. Version 3.2014:http: \/\/ www.nccn.org\/professionals\/physician_gls\/PDF\/anemia.pdf . Accessed 3 Jun 2014"},{"issue":"Suppl 5","key":"3078_CR49","doi-asserted-by":"crossref","first-page":"v244","DOI":"10.1093\/annonc\/mdq202","volume":"21","author":"D Schrijvers","year":"2010","unstructured":"Schrijvers D, De Samblanx H, Roila F (2010) Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol : Off J Eur Soc Med Oncol \/ ESMO 21(Suppl 5):v244\u2013247","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol \/ ESMO"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3078-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-016-3078-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3078-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T09:15:38Z","timestamp":1600161338000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-016-3078-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,12]]},"references-count":49,"alternative-id":["3078"],"URL":"https:\/\/doi.org\/10.1007\/s00520-016-3078-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2016,2,12]]}}}